Indications
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Composition
- Active substance
- nonacog gamma
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rixubis
- Active substance
- nonacog gamma
- ATC code
- B02BD04
- Therapeutic area
- Hemophilia B
- Marketing authorisation holder
- Baxalta Innovations GmbH
- Status
- Authorised
- EU authorisation
- 19 Dec 2014
- EMA product number